PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organization, has appointed Imogene Grimes, Ph.D., to Vice President of Data Sciences Strategic Services. Dr. Grimes, a leading biostatistician with more than 25 years of experience, is contributing to the continued expansion of PAREXEL’s data science services, including data management, biostatistics, and applications of information technology to the clinical development process.

PAREXEL International Corporation (NASDAQ: PRXL) today announced its financial results for the third quarter and nine months ended March 31, 2008. The past and current period results reflect a two-for-one stock split which occurred on March 3, 2008.

Perceptive Informatics, the technology subsidiary of PAREXEL International Corporation (NASDAQ: PRXL), today announced the availability of its clinical site management and monitoring software, IMPACT® MySites, on a portable USB drive. Clinical monitors can now securely upload site visit information onto the USB drive, without carrying their laptop computers with them. The MySites monitoring solution is a part of the IMPACT suite, Perceptive Informatics’ market-leading Clinical Trial Management System (CTMS).

Senior experts from PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, will discuss best practices for successful partnerships at the 17th Annual Partnerships with CROs conference, to be held April 14-16, 2008 in Las Vegas, Nevada. PAREXEL is an Associate Sponsor of the conference. PAREXEL experts will present in the following sessions, which address the implementation of metrics to enhance partnership performance, and strategies to successfully leverage emerging markets for global clinical trials.

PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced that Larry Ereshefsky, Pharm.D., F.C.C.P., B.C.C.P., and Malek Bajbouj, M.D., have been appointed as Vice Presidents of Clinical Pharmacology Consulting Services in the Company’s international clinical pharmacology business. These leading experts advise clients on early phase clinical development in the central nervous system (CNS) therapeutic area, including in regard to psychiatry, neuropsychopharmacology, and neurophysiology clinical studies. Dr. Ereshefsky is based at PAREXEL’s Clinical Pharmacology Research Unit in Los Angeles, California in the United States and Dr. Bajbouj is based at the unit in Berlin, Germany.

PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that the Company had completed the expansion of three Clinical Pharmacology Research Units located in Baltimore, Maryland in the United States; London, United Kingdom; and Berlin, Germany in order to meet growing client demand for expertise-based studies in the early phases of clinical development.

PAREXEL International Corporation (“PAREXEL”) (NASDAQ: PRXL) today announced that it has expanded its minority interest ownership in the clinical pharmacology business of Synchron Research in Ahmedabad, India.

PAREXEL International Corporation (NASDAQ: PRXL) will release Third Quarter Fiscal Year 2008 financial results on Wednesday, April 23, 2008 after the close of the stock market.

PAREXEL International Corporation (NASDAQ: PRXL) announced today it will be presenting at the Bank of America 2008 Smid Cap Conference.

PAREXEL International Corporation (NASDAQ: PRXL), a leading global bio/pharmaceutical services organization, has appointed Jacque Fisher as a Vice President and General Manager in the Company’s Medical Communications Services business.

PAREXEL International Corporation (NASDAQ: PRXL) announced today it will be presenting at the Lehman Brothers 11th Annual Global Healthcare Conference in Miami, Florida.

PAREXEL International Corporation (NASDAQ: PRXL) announced today it will be presenting at the Raymond James 29th Annual Institutional Investors Conference at the Hyatt Regency Grand Cypress in Orlando, Florida.

Experts from PAREXEL International Corporation (NASDAQ: PRXL), a leading global bio/pharmaceutical services provider, will present on key topics at the Drug Information Association’s (DIA) 20th Annual EuroMeeting in Barcelona, Spain being held March 3 – 5, 2008.

PAREXEL International Corporation ("PAREXEL") (Nasdaq: PRXL) notes the recent movement in the share price of ClinPhone plc ("ClinPhone" or the "Company").

PAREXEL International Corporation (NASDAQ: PRXL) announced today that its Board of Directors has approved a 2-for-1 split of its Common Stock, which will be effected by means of a 100% stock dividend.

PAREXEL International Corporation (NASDAQ: PRXL) today announced its financial results for the second quarter ended December 31, 2007.

PAREXEL International Corporation (NASDAQ: PRXL), a leading global bio/pharmaceutical services organization, today announced that Eduard E. Holdener, M.D., formerly Head of Global Pharmaceutical Development at F. Hoffmann-La Roche, Ltd., has been elected to its Board of Directors.

PAREXEL International Corporation (Nasdaq: PRXL) announced today it will be presenting at the 26th Annual JPMorgan Healthcare Conference at The Westin St. Francis in San Francisco.